BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012;50:3-13. [PMID: 22554854 DOI: 10.1016/j.resinv.2012.02.001] [Cited by in Crossref: 162] [Cited by in F6Publishing: 161] [Article Influence: 16.2] [Reference Citation Analysis]
Number Citing Articles
1 Macri A, Stoica R. Alveolar proteinosis – disease with unpredictable evolution (series of clinical cases). Pneumologia 2019;68:183-93. [DOI: 10.2478/pneum-2019-0029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Kishaba T, Nagano H, Nei Y, Yamashiro S. Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis 2016;8:1112-20. [PMID: 27293827 DOI: 10.21037/jtd.2016.03.89] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kuwana M, Shirai Y, Takeuchi T. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease. J Rheumatol 2016;43:1825-31. [DOI: 10.3899/jrheum.160339] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
4 Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2012;18:441-446. [PMID: 22847105 DOI: 10.1097/mcp.0b013e328356d03c] [Cited by in Crossref: 69] [Cited by in F6Publishing: 34] [Article Influence: 6.9] [Reference Citation Analysis]
5 Papasavvas I, Gehrig B, Herbort CP Jr. The Comparative Value of Serum Angiotensin Converting Enzyme (ACE) and Lysozyme and the Use of Polyclonal Antibody Activation in the Work-up of Ocular Sarcoidosis. Diagnostics (Basel) 2021;11:608. [PMID: 33805490 DOI: 10.3390/diagnostics11040608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
6 Wang Y, Chen S, Zheng S, Lin J, Hu S, Zhuang J, Lin Q, Xie X, Zheng K, Zhang W, Du G, Zhang G, Hoffmann-Vold AM, Matucci-Cerinic M, Furst DE. The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. Arthritis Res Ther 2021;23:212. [PMID: 34391465 DOI: 10.1186/s13075-021-02586-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Lee JS, Lee EY, Ha YJ, Kang EH, Lee YJ, Song YW. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther 2019;21:58. [PMID: 30764869 DOI: 10.1186/s13075-019-1835-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
8 Ballester B, Milara J, Cortijo J. The role of mucin 1 in respiratory diseases. Eur Respir Rev 2021;30:200149. [PMID: 33536260 DOI: 10.1183/16000617.0149-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Arai T, Tachibana K, Sugimoto C, Inoue Y, Tokura S, Okuma T, Akira M, Kitaichi M, Hayashi S, Inoue Y. High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias: Prednisolone improves AE in IIPs. Respirology 2017;22:1363-70. [DOI: 10.1111/resp.13065] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
10 Bonhomme O, André B, Gester F, de Seny D, Moermans C, Struman I, Louis R, Malaise M, Guiot J. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology (Oxford) 2019;58:1534-46. [PMID: 31292645 DOI: 10.1093/rheumatology/kez230] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
11 Nouno T, Okamoto M, Ohnishi K, Kaieda S, Tominaga M, Zaizen Y, Ichiki M, Momosaki S, Nakamura M, Fujimoto K, Fukuoka J, Shimizu S, Komohara Y, Hoshino T. Elevation of pulmonary CD163+ and CD204+ macrophages is associated with the clinical course of idiopathic pulmonary fibrosis patients. J Thorac Dis. 2019;11:4005-4017. [PMID: 31656675 DOI: 10.21037/jtd.2019.09.03] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
12 Horimasu Y, Ishikawa N, Tanaka S, Hirano C, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, Kohno N. MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study. BMC Cancer 2017;17:263. [PMID: 28403862 DOI: 10.1186/s12885-017-3272-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Śliwińska-Mossoń M, Wadowska K, Trembecki Ł, Bil-Lula I. Markers Useful in Monitoring Radiation-Induced Lung Injury in Lung Cancer Patients: A Review. J Pers Med 2020;10:E72. [PMID: 32722546 DOI: 10.3390/jpm10030072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tagami Y, Hara Y, Murohashi K, Nagasawa R, Nishikawa Y, Tanaka M, Aoki A, Tanaka K, Nakashima K, Watanabe K, Horita N, Kobayashi N, Yamamoto M, Kudo M, Okudela K, Kaneko T. Comparison of Clinical Features between the High and Low Serum KL-6 Patients with Acute Exacerbation of Interstitial Lung Diseases. Can Respir J 2021;2021:9099802. [PMID: 34887972 DOI: 10.1155/2021/9099802] [Reference Citation Analysis]
15 Isaka E, Sugiura T, Hashimoto K, Kikuta K, Anazawa U, Nomura T, Kameyama A. Characterization of tumor-associated MUC1 and its glycans expressed in mucoepidermoid carcinoma. Oncol Lett 2021;22:702. [PMID: 34457057 DOI: 10.3892/ol.2021.12963] [Reference Citation Analysis]
16 Liu X, Shao C, Fu J. Promising Biomarkers of Radiation-Induced Lung Injury: A Review. Biomedicines 2021;9:1181. [PMID: 34572367 DOI: 10.3390/biomedicines9091181] [Reference Citation Analysis]
17 Yang WM, Chen JJ. Advances in biomarkers for dermatomyositis. Clin Chim Acta 2018;482:172-7. [PMID: 29614309 DOI: 10.1016/j.cca.2018.03.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Nahar S, Nakamoto M, Hokama A, Kobashigawa C, Kaida M, Kinjo T, Hirata T, Kinjo N, Saio M, Yoshimi N, Ohtsuki Y, Fujita J. Peritoneal Malignant Mesothelioma with Epithelioid Type, Demonstrating High Serum and Ascitic KL-6 Levels: Immunohistochemical Analyses. Rare Tumors 2015;7:5947. [PMID: 26500734 DOI: 10.4081/rt.2015.5947] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Mavi AK, Spalgais S, Singh K, Kumar U, Kumar R. Expression profile of MUC1 protein in Pigeon allergens positive asthmatic. Immunobiology 2021;226:152086. [PMID: 33784545 DOI: 10.1016/j.imbio.2021.152086] [Reference Citation Analysis]
20 Wakamatsu K, Nagata N, Kumazoe H, Oda K, Ishimoto H, Yoshimi M, Takata S, Hamada M, Koreeda Y, Takakura K, Ishizu M, Hara M, Ise S, Izumi M, Akasaki T, Maki S, Kawabata M, Mukae H, Kawasaki M. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig 2017;55:16-23. [PMID: 28012488 DOI: 10.1016/j.resinv.2016.09.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
21 Ishikawa N, Hattori N, Kohno N, Kobayashi A, Hayamizu T, Johnson M. Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controls. Int J Chron Obstruct Pulmon Dis 2015;10:185-92. [PMID: 25670894 DOI: 10.2147/COPD.S74557] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
22 Arai T, Hirose M, Hamano Y, Kagawa T, Murakami A, Kida H, Kumanogoh A, Inoue Y, Roth M. Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis. Canadian Respiratory Journal 2022;2022:1-10. [DOI: 10.1155/2022/1107673] [Reference Citation Analysis]
23 Sokai A, Tanizawa K, Handa T, Kanatani K, Kubo T, Ikezoe K, Nakatsuka Y, Tokuda S, Oga T, Hirai T, Nagai S, Chin K, Mishima M. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res 2017;3:00019-2016. [PMID: 28875146 DOI: 10.1183/23120541.00019-2016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
24 Yamada S, Kajihara I, Johno T, Fukushima S, Jinnin M, Masunaga A, Kohrogi H, Ihn H. Symptomless Pulmonary Cryptococcosis in a Psoriatic Arthritis Patient during Infliximab Therapy. Ann Dermatol 2016;28:269-70. [PMID: 27081286 DOI: 10.5021/ad.2016.28.2.269] [Reference Citation Analysis]
25 Yamane H, Ochi N, Yamagishi T, Honda Y, Takeyama M, Takigawa N. Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study. Ther Clin Risk Manag 2015;11:949-59. [PMID: 26124663 DOI: 10.2147/TCRM.S82995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Wang J, Zheng P, Huang Z, Huang H, Xue M, Liao C, Sun B, Zhong N. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features. BMC Pulm Med 2020;20:315. [PMID: 33267857 DOI: 10.1186/s12890-020-01336-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Hoffmann-vold A, Fretheim H, Meier C, Maurer B. Circulating biomarkers of systemic sclerosis – interstitial lung disease. Journal of Scleroderma and Related Disorders 2020;5:41-7. [DOI: 10.1177/2397198319894851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Casanova NG, Zhou T, Gonzalez-Garay ML, Lussier YA, Sweiss N, Ma SF, Noth I, Knox KS, Garcia JGN. MicroRNA and protein-coding gene expression analysis in idiopathic pulmonary fibrosis yields novel biomarker signatures associated to survival. Transl Res 2021;228:1-12. [PMID: 32711186 DOI: 10.1016/j.trsl.2020.07.009] [Reference Citation Analysis]
29 Kishaba T, Nagano H, Nei Y, Yamashiro S. Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis 2016;8:3596-604. [PMID: 28149554 DOI: 10.21037/jtd.2016.12.49] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
30 Tagaya Y, Okada S, Hisada T, Niijima Y, Yamada M. Interstitial pneumonia during administration of dipeptidyl peptidase-4 inhibitors. J Diabetes. 2016;8:442. [PMID: 26678559 DOI: 10.1111/1753-0407.12359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Cho EJ, Park KJ, Ko DH, Koo HJ, Lee SM, Song JW, Lee W, Lee HK, Do KH, Chun S, Min WK. Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases. Ann Lab Med 2019;39:245-51. [PMID: 30623616 DOI: 10.3343/alm.2019.39.3.245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Shoji T, Niida Y, Osawa T, Matsumoto R, Sakurai K, Suzuki M, Matsuno Y, Konno S. Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex. Respir Med Case Rep 2021;34:101526. [PMID: 34703757 DOI: 10.1016/j.rmcr.2021.101526] [Reference Citation Analysis]
33 Masuda T, Hirano C, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2018;81:131-9. [PMID: 29143072 DOI: 10.1007/s00280-017-3476-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
34 Juge PA, Crestani B, Dieudé P. Recent advances in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Pulm Med 2020;26:477-86. [PMID: 32701675 DOI: 10.1097/MCP.0000000000000710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Tanaka N, Nishimura K, Waki D, Kadoba K, Murabe H, Yokota T. Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol 2021;:1-12. [PMID: 33496209 DOI: 10.1080/14397595.2021.1879346] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Shah RR. Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas. Drug Saf. 2016;39:1073-1091. [PMID: 27534751 DOI: 10.1007/s40264-016-0450-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
37 Robinson MB, Deshpande DA, Chou J, Cui W, Smith S, Langefeld C, Hastie AT, Bleecker ER, Hawkins GA. IL-6 trans-signaling increases expression of airways disease genes in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2015;309:L129-38. [PMID: 26001777 DOI: 10.1152/ajplung.00288.2014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
38 Remuzgo-Martínez S, Atienza-Mateo B, Ocejo-Vinyals JG, Genre F, Pulito-Cueto V, Mora-Cuesta VM, Iturbe-Fernández D, Lera-Gómez L, Pérez-Fernández R, Prieto-Peña D, Irure J, Romero-Bueno F, Sanchez-Pernaute O, Alonso-Moralejo R, Nuño L, Bonilla G, Vicente-Rabaneda EF, Grafia I, Prieto-González S, Narvaez J, Trallero-Araguas E, Selva-O'Callaghan A, Gualillo O, Cavagna L, Cifrián JM, Renzoni EA, Castañeda S, López-Mejías R, González-Gay MA; Spanish Biomarkers of Antisynthetase Syndrome Consortium., Spanish Biomarkers of Interstitial Lung Disease Consortium. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. Sci Rep 2021;11:22574. [PMID: 34799647 DOI: 10.1038/s41598-021-01992-y] [Reference Citation Analysis]
39 Kishaba T. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Medicina (Kaunas) 2019;55:E70. [PMID: 30884853 DOI: 10.3390/medicina55030070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
40 Wakamoto H, Sano N, Yano Y, Sakai S, Kikuchi T, Fukuda M, Morimoto T, Ishii E. Clinical Usefulness of Serum Krebs von den Lungen-6 for Detecting Chronic Aspiration in Children with Severe Motor and Intellectual Disabilities. J Pediatr 2015;167:1136-42. [PMID: 26382626 DOI: 10.1016/j.jpeds.2015.08.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Rangappa S, Artigas G, Miyoshi R, Yokoi Y, Hayakawa S, Garcia-martin F, Hinou H, Nishimura S. Effects of the multiple O-glycosylation states on antibody recognition of the immunodominant motif in MUC1 extracellular tandem repeats. Med Chem Commun 2016;7:1102-22. [DOI: 10.1039/c6md00100a] [Cited by in Crossref: 25] [Cited by in F6Publishing: 1] [Article Influence: 4.2] [Reference Citation Analysis]
42 Ohtsuki Y, Watanabe R, Kimura M, Nomura K, Maeda T, Kito K, Takeji M, Lee GH, Furihata M. Usefulness of KL-6 in the subtyping of intraductal papillary mucinous neoplasia of the pancreas, including carcinoma, dysplasia, and hyperplasia. Med Mol Morphol 2015;48:85-91. [PMID: 24908068 DOI: 10.1007/s00795-014-0080-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Moll SA, Wiertz IA, Vorselaars AD, Zanen P, Ruven HJ, van Moorsel CH, Grutters JC. Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis. Biomark Med 2020;14:997-1007. [PMID: 32940077 DOI: 10.2217/bmm-2020-0165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Baroke E, Gauldie J, Kolb M. New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research. Expert Rev Respir Med 2013;7:465-78. [PMID: 24138691 DOI: 10.1586/17476348.2013.838015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
45 Salvador-corres I, Quirant-sanchez B, Teniente-serra A, Centeno C, Moreno A, Rodríguez-pons L, Serra-mitjá P, García-nuñez M, Martinez-caceres E, Rosell A, Olivé A, Portillo K. Detection of autoantibodies in bronchoalveolar lavage in patients with diffuse interstitial lung disease. Archivos de Bronconeumología (English Edition) 2021;57:351-8. [DOI: 10.1016/j.arbr.2021.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
46 Zhu Y, Fu J, You K, Jin L, Wang M, Lu D, Xue X. Changes in pulmonary tissue structure and KL-6/MUC1 expression in a newborn rat model of hyperoxia-induced bronchopulmonary dysplasia. Exp Lung Res 2013;39:417-26. [PMID: 24298937 DOI: 10.3109/01902148.2013.810795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease. J Rheumatol 2019;46:935-42. [DOI: 10.3899/jrheum.180825] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
48 Awano N, Inomata M, Kuse N, Tone M, Takada K, Muto Y, Fujimoto K, Akagi Y, Mawatari M, Ueda A, Izumo T. Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019. Respir Investig 2020:S2212-5345(20)30115-5. [PMID: 32863199 DOI: 10.1016/j.resinv.2020.07.004] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
49 Oguz EO, Kucuksahin O, Turgay M, Yildizgoren MT, Ates A, Demir N, Kumbasar OO, Kinikli G, Duzgun N. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study. Clin Rheumatol 2016;35:663-6. [PMID: 26758437 DOI: 10.1007/s10067-015-3167-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
50 d’Alessandro M, Bergantini L, Cameli P, Vietri L, Lanzarone N, Alonzi V, Pieroni M, M refini R, Sestini P, Bonella F, Bargagli E. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. Biomarkers in Medicine 2020;14:665-74. [DOI: 10.2217/bmm-2019-0545] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
51 Shvedova AA, Yanamala N, Kisin ER, Khailullin TO, Birch ME, Fatkhutdinova LM. Integrated Analysis of Dysregulated ncRNA and mRNA Expression Profiles in Humans Exposed to Carbon Nanotubes. PLoS One 2016;11:e0150628. [PMID: 26930275 DOI: 10.1371/journal.pone.0150628] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
52 Ballester B, Milara J, Montero P, Cortijo J. MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-β1 Canonical Pathway. Int J Mol Sci 2021;22:6502. [PMID: 34204432 DOI: 10.3390/ijms22126502] [Reference Citation Analysis]
53 Ohyabu N, Kakiya K, Yokoi Y, Hinou H, Nishimura S. Convergent Solid-Phase Synthesis of Macromolecular MUC1 Models Truly Mimicking Serum Glycoprotein Biomarkers of Interstitial Lung Diseases. J Am Chem Soc 2016;138:8392-5. [DOI: 10.1021/jacs.6b04973] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
54 Yamaya T, Hagiwara E, Baba T, Kitayama T, Murohashi K, Higa K, Sato Y, Otoshi R, Tabata E, Shintani R, Okabayashi H, Ikeda S, Niwa T, Nakazawa A, Oda T, Okuda R, Sekine A, Kitamura H, Komatsu S, Ogura T. Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019. Respir Investig 2021;59:596-601. [PMID: 33965361 DOI: 10.1016/j.resinv.2021.04.002] [Reference Citation Analysis]
55 Kato T, Ujiie H, Hatanaka KC, Nange A, Okumura A, Tsubame K, Naruchi K, Sato M, Kaga K, Matsuno Y, Wakasa S, Hatanaka Y. A novel Tn antigen epitope-recognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma. Oncol Lett 2021;21:202. [PMID: 33574941 DOI: 10.3892/ol.2021.12463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Hayashi M, Yanaba K, Umezawa Y, Asahina A, Nakagawa H. Impact of anti-tumor necrosis factor-α agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis. J Dermatol 2017;44:1063-6. [PMID: 28370220 DOI: 10.1111/1346-8138.13837] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
57 Shanshan L, Yamei Z, Ling Z, Xin L, Guochun W. Progranulin correlated with rapid progressive interstitial lung disease in dermatomyositis with anti-melanoma differentiation-associated gene 5 antibody. Clin Rheumatol 2021. [PMID: 34718893 DOI: 10.1007/s10067-021-05816-2] [Reference Citation Analysis]
58 Zheng P, Liu X, Huang H, Guo Z, Wu G, Hu H, Cai C, Luo W, Wei N, Han Q, Sun B. Diagnostic value of KL-6 in idiopathic interstitial pneumonia. J Thorac Dis 2018;10:4724-32. [PMID: 30233844 DOI: 10.21037/jtd.2018.07.54] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
59 Kilinc AA, Arslan A, Yildiz M, Kucur M, Adrovic A, Barut K, Sahin S, Cokugras H, Kasapcopur O. Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study. Rheumatol Int 2020;40:1701-6. [DOI: 10.1007/s00296-019-04485-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
60 Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Kohno N, Hattori N. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody: A retrospective cohort study. Medicine (Baltimore) 2018;97:e13542. [PMID: 30544464 DOI: 10.1097/MD.0000000000013542] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Noguchi S, Eitoku M, Kiyosawa H, Suganuma N. Fibrotic gene expression coexists with alveolar proteinosis in early indium lung. Inhalation Toxicology 2016;28:421-8. [DOI: 10.1080/08958378.2016.1193573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
62 Horii H, Kamada K, Nakakubo S, Yamashita Y, Nakamura J, Nasuhara Y, Konno S. Rapidly progressive organizing pneumonia associated with COVID-19. Respir Med Case Rep 2020;31:101295. [PMID: 33224726 DOI: 10.1016/j.rmcr.2020.101295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Hanaoka M, Katsumata Y, Kawasumi H, Kawaguchi Y, Yamanaka H. KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker. Modern Rheumatology 2019;29:625-32. [DOI: 10.1080/14397595.2018.1553488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
64 Zheng P, Zheng X, Takehiro H, Cheng ZJ, Wang J, Xue M, Lin Q, Huang Z, Huang H, Liao C, Sun B. The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease. J Transl Int Med 2021;9:212-22. [PMID: 34900632 DOI: 10.2478/jtim-2021-0040] [Reference Citation Analysis]
65 Stainer A, Faverio P, Busnelli S, Catalano M, Della Zoppa M, Marruchella A, Pesci A, Luppi F. Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions. Int J Mol Sci 2021;22:6255. [PMID: 34200784 DOI: 10.3390/ijms22126255] [Reference Citation Analysis]
66 Nakayama Y, Ikeda M, Kojima M, Goto K, Hara M, Okuyama H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Okusaka T. Successful Everolimus Treatment in a Patient with Advanced Pancreatic Neuroendocrine Tumor Who Developed Everolimus-Induced Interstitial Lung Disease on Two Occasions: A Case Report. Chemotherapy 2013;59:74-8. [DOI: 10.1159/000351103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
67 Moll SA, Wiertz IA, Vorselaars ADM, Ruven HJT, van Moorsel CHM, Grutters JC. Change in Serum Biomarker CA 15-3 as an Early Predictor of Response to Treatment and Survival in Hypersensitivity Pneumonitis. Lung 2020;198:385-93. [PMID: 31993739 DOI: 10.1007/s00408-020-00330-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Wang Y, Chen S, Lin Z, Du G, Lin J, Lin Q, Xiufeng H, Zhang G, Furst DE, Gargani L, Matucci-cerinic M. Imaging and serum biomarkers in connective tissue disease–associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levels. Ann Rheum Dis 2019;78:573-5. [DOI: 10.1136/annrheumdis-2018-214098] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
69 Kitahara Y, Taniyama D, Kuraoka K, Saito A, Zaitsu J, Oga K, Senoo M, Araki Y, Yamaguchi A, Nakano K. Lymphangitis carcinomatosa from gallbladder cancer. Respiratory Medicine Case Reports 2022;37:101621. [DOI: 10.1016/j.rmcr.2022.101621] [Reference Citation Analysis]
70 Okamoto M, Izuhara K, Ohta S, Ono J, Hoshino T. Ability of Periostin as a New Biomarker of Idiopathic Pulmonary Fibrosis. Adv Exp Med Biol 2019;1132:79-87. [PMID: 31037627 DOI: 10.1007/978-981-13-6657-4_9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
71 Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic Pulmonary Fibrosis (IPF): An Overview. J Clin Med 2018;7:E201. [PMID: 30082599 DOI: 10.3390/jcm7080201] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 19.8] [Reference Citation Analysis]
72 Shirai Y, Fukue R, Kaneko Y, Kuwana M. Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. Diagnostics (Basel) 2021;11:2007. [PMID: 34829353 DOI: 10.3390/diagnostics11112007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Berastegui C, Gómez-Ollés S, Mendoza-Valderrey A, Pereira-Veiga T, Culebras M, Monforte V, Saez B, López-Meseguer M, Sintes-Permanyer H, Ruiz de Miguel V, Bravo C, Sacanell J, Ramon MA, Romero L, Deu M, Román A. Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation. PLoS One 2020;15:e0226488. [PMID: 31929536 DOI: 10.1371/journal.pone.0226488] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
74 Sakai M, Kubota T, Ohnishi H, Yokoyama A. A novel lung injury animal model using KL-6-measurable human MUC1-expressing mice. Biochem Biophys Res Commun 2013;432:460-5. [PMID: 23410752 DOI: 10.1016/j.bbrc.2013.01.123] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
75 Campo I, Zorzetto M, Bonella F. Facts and promises on lung biomarkers in interstitial lung diseases. Expert Review of Respiratory Medicine 2015;9:437-57. [DOI: 10.1586/17476348.2015.1062367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
76 Arai T, Akira M, Sugimoto C, Tachibana K, Inoue Y, Shintani S, Okuma T, Kasai T, Hayashi S, Inoue Y. Seroradiologic prognostic evaluation of acute exacerbation in patients with idiopathic interstitial pneumonia: a retrospective observational study. J Thorac Dis 2020;12:4132-47. [PMID: 32944325 DOI: 10.21037/jtd-20-911] [Reference Citation Analysis]
77 Ahmed S, Pattanaik SS, Rai MK, Nath A, Agarwal V. Interstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies. Mediterr J Rheumatol 2018;29:140-7. [PMID: 32185315 DOI: 10.31138/mjr.29.3.140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
78 Yamane H, Ochi N, Nagasaki Y, Yamagishi T, Honda Y, Nakagawa N, Takeyama M, Nakanishi H, Takigawa N. Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17. Ther Clin Risk Manag 2018;14:1457-65. [PMID: 30174428 DOI: 10.2147/TCRM.S169824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Okuda R, Matsushima H, Aoshiba K, Oba T, Kawabe R, Honda K, Amano M. Soluble intercellular adhesion molecule-1 for stable and acute phases of idiopathic pulmonary fibrosis. Springerplus 2015;4:657. [PMID: 26543791 DOI: 10.1186/s40064-015-1455-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
80 Miyazaki Y, Tsutsui T, Inase N. Treatment and monitoring of hypersensitivity pneumonitis. Expert Review of Clinical Immunology 2016;12:953-62. [DOI: 10.1080/1744666x.2016.1182426] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
81 Wang Y, Chen S, Lin J, Xie X, Hu S, Lin Q, Zheng K, Du G, Huang X, Zhang G, Gargani L, Matucci-Cerinic M, Furst DE. Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease. Rheumatology (Oxford) 2020;59:2024-9. [PMID: 31794028 DOI: 10.1093/rheumatology/kez571] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
82 Bando M, Sugiyama Y, Azuma A, Ebina M, Taniguchi H, Taguchi Y, Takahashi H, Homma S, Nukiwa T, Kudoh S. A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan. Respiratory Investigation 2015;53:51-9. [DOI: 10.1016/j.resinv.2014.11.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
83 Kahn N, Rossler AK, Hornemann K, Muley T, Grünig E, Schmidt W, Herth FJF, Kreuter M. C-proSP-B: A Possible Biomarker for Pulmonary Diseases? Respiration 2018;96:117-26. [PMID: 29763900 DOI: 10.1159/000488245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
84 Yamaguchi K, Yamaguchi A, Itai M, Onuki Y, Shin Y, Uno S, Hanazato C, Taguchi K, Umetsu K, Aikawa M, Kouno S, Takemura M, Hara K, Motegi S, Tsukida M, Ota F, Tsukada Y, Motegi M, Nakasatomi M, Sakairi T, Ikeuchi H, Kaneko Y, Hiromura K, Maeno T. Interstitial lung disease with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis in elderly patients. Rheumatol Int 2021;41:1641-50. [PMID: 34056682 DOI: 10.1007/s00296-021-04891-7] [Reference Citation Analysis]
85 Ballester B, Milara J, Cortijo J. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets. Int J Mol Sci 2019;20:E593. [PMID: 30704051 DOI: 10.3390/ijms20030593] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 18.0] [Reference Citation Analysis]
86 Vianello A, Guarnieri G, Braccioni F, Lococo S, Molena B, Cecchetto A, Giraudo C, Bertagna De Marchi L, Caminati M, Senna G. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med 2021. [PMID: 34783228 DOI: 10.1515/cclm-2021-1021] [Reference Citation Analysis]
87 Gomes PS, Soares MR, Marchenta MFML, Meirelles GSP, Ferreira RG, Botelho AB, Martins RB, Pereira CAC. Carbohydrate antigen 15-3 as a marker of disease severity in patients with chronic hypersensitivity pneumonitis. J Bras Pneumol 2021;47:e20200589. [PMID: 33681879 DOI: 10.36416/1806-3756/e20200589] [Reference Citation Analysis]
88 Huang TH, Kuo CW, Chen CW, Tseng YL, Wu CL, Lin SH. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study. BMC Pulm Med 2021;21:165. [PMID: 33992083 DOI: 10.1186/s12890-021-01530-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Ishii H, Kushima H, Kinoshita Y, Fujita M, Watanabe K. The serum KL-6 levels in untreated idiopathic pulmonary fibrosis can naturally decline in association with disease progression. Clin Respir J 2018;12:2411-8. [PMID: 30015394 DOI: 10.1111/crj.12946] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
90 Imai R, Yamada D, Tomishima Y, Nakamura T, So C, Ro S, Okafuji K, Kitamura A, Jinta T, Nishimura N. Elevated plasma levels of Krebs von den Lungen-6 and geographic appearance on high-resolution computed tomography are associated with diffuse alveolar damage in autopsy cases of acute respiratory distress syndrome: a retrospective study. BMC Pulm Med 2022;22:308. [PMID: 35953795 DOI: 10.1186/s12890-022-02102-y] [Reference Citation Analysis]
91 d’Alessandro M, Bergantini L, Cameli P, Lanzarone N, Antonietta Mazzei M, Alonzi V, Sestini P, Bargagli E. Serum KL‐6 levels in pulmonary Langerhans’ cell histiocytosis. Eur J Clin Invest 2020;50. [DOI: 10.1111/eci.13242] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
92 Choi MG, Choi SM, Lee JH, Yoon JK, Song JW. Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease. Sci Rep 2022;12:4916. [PMID: 35318424 DOI: 10.1038/s41598-022-08965-9] [Reference Citation Analysis]
93 Salazar GA, Kuwana M, Wu M, Estrada-Y-Martin RM, Ying J, Charles J, Mayes MD, Assassi S. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease. J Rheumatol 2018;45:1153-8. [PMID: 29961690 DOI: 10.3899/jrheum.170518] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
94 Lee JS, Kim GJ, Ha YJ, Kang EH, Lee YJ, Goldin JG, Lee EY. The Extent and Diverse Trajectories of Longitudinal Changes in Rheumatoid Arthritis Interstitial Lung Diseases Using Quantitative HRCT Scores. J Clin Med 2021;10:3812. [PMID: 34501260 DOI: 10.3390/jcm10173812] [Reference Citation Analysis]
95 Ballester B, Milara J, Cortijo J. Mucins as a New Frontier in Pulmonary Fibrosis. J Clin Med 2019;8:E1447. [PMID: 31514468 DOI: 10.3390/jcm8091447] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
96 d'Alessandro M, Bergantini L, Cameli P, Pieroni M, Refini RM, Sestini P, Bargagli E. Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy. Cancers (Basel) 2021;13:689. [PMID: 33572070 DOI: 10.3390/cancers13040689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
97 Wang J, Huang Z, Xue M, Huang H, Zheng X, Zhong N, Sun B. Evaluation of the clinical performance of the HISCL-5000 analyzer in the detection of Krebs von den Lungen-6 antigen and its diagnostic value in interstitial lung disease. J Clin Lab Anal 2020;34:e23070. [PMID: 31691368 DOI: 10.1002/jcla.23070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Majewski S, Szewczyk K, Żal A, Białas AJ, Miłkowska-Dymanowska J, Piotrowski WJ. Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study. J Clin Med 2021;10:3864. [PMID: 34501312 DOI: 10.3390/jcm10173864] [Reference Citation Analysis]
99 Rieder F, de Bruyn JR, Pham BT, Katsanos K, Annese V, Higgins PD, Magro F, Dotan I. Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis. 2014;8:1166-1178. [PMID: 24726695 DOI: 10.1016/j.crohns.2014.03.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
100 Blasi F, Tarsia P, Mantero M, Morlacchi LC, Piffer F. Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. Ther Clin Risk Manag 2013;9:55-64. [PMID: 23430960 DOI: 10.2147/TCRM.S41131] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
101 Bonella F, Ohshimo S, Miaotian C, Griese M, Guzman J, Costabel U. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis. Orphanet J Rare Dis 2013;8:53. [PMID: 23557396 DOI: 10.1186/1750-1172-8-53] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
102 Odashima K, Kagiyama N, Kanauchi T, Ishiguro T, Takayanagi N. Incidence and etiology of chronic pulmonary infections in patients with idiopathic pulmonary fibrosis. PLoS One 2020;15:e0230746. [PMID: 32243456 DOI: 10.1371/journal.pone.0230746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Imai R, Nishimura N, Takahashi O, Tamura T. High-resolution computed tomography for the prediction of mortality in acute respiratory distress syndrome: A retrospective cohort study. Health Sci Rep 2021;4:e418. [PMID: 34646945 DOI: 10.1002/hsr2.418] [Reference Citation Analysis]
104 Ohji H, Shinohara T, Kadota N, Okano Y, Naruse K, Iwahara Y, Ogushi F. Pneumocystis jirovecii pneumonia in an HIV-infected patient mimicking acute eosinophilic pneumonia: a case report with a review of the literature. J Thorac Dis 2018;10:E774-8. [PMID: 30622810 DOI: 10.21037/jtd.2018.10.49] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Nathan N, Corvol H, Amselem S, Clement A. Biomarkers in Interstitial lung diseases. Paediatric Respiratory Reviews 2015;16:219-24. [DOI: 10.1016/j.prrv.2015.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
106 Kashiwabara K, Semba H, Fujii S, Tsumura S, Aoki R. The Ratio KL-6 to SLX in Serum for Prediction of the Occurrence of Drug-Induced Interstitial Lung Disease in Lung Cancer Patients with Idiopathic Interstitial Pneumonias Receiving Chemotherapy. Cancer Invest 2015;33:516-21. [PMID: 26305851 DOI: 10.3109/07357907.2015.1069832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
107 Shiraishi K, Jinta T, Nishimura N, Nakaoka H, Tsugitomi R, Okafuji K, Kitamura A, Tomishima Y, Deshpande GA, Tamura T. Digital Clubbing Is Associated with Higher Serum KL-6 Levels and Lower Pulmonary Function in Patients with Interstitial Lung Disease. Can Respir J 2018;2018:3640967. [PMID: 29610629 DOI: 10.1155/2018/3640967] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
108 Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, Brown KK. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest 2020;158:646-59. [PMID: 32268131 DOI: 10.1016/j.chest.2020.03.037] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
109 Cicco S, Leone P, Racanelli V, Vacca A. Mucine-1 Is Related to Cell-Mediated Immunoexpression and Blood Pressure in Pulmonary Artery in Pulmonary Arterial Hypertension (PAH): Preliminary Results. Adv Exp Med Biol 2018;1072:275-80. [PMID: 30178358 DOI: 10.1007/978-3-319-91287-5_44] [Reference Citation Analysis]
110 Hu Y, Wang LS, Jin YP, Du SS, Du YK, He X, Weng D, Zhou Y, Li QH, Shen L, Zhang F, Su YL, Sun XL, Ding JJ, Zhang WH, Cai HR, Dai HP, Dai JH, Li HP. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients. Clin Respir J 2017;11:337-45. [PMID: 26077281 DOI: 10.1111/crj.12341] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
111 Scotto R, Pinchera B, Perna F, Atripaldi L, Giaccone A, Sequino D, Zappulo E, Sardanelli A, Schiano Moriello N, Stanziola A, Bocchino M, Gentile I, Sanduzzi A. Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia. Int J Environ Res Public Health 2021;18:2078. [PMID: 33672761 DOI: 10.3390/ijerph18042078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
112 Ishii H, Watanabe K, Kushima H, Baba T, Watanabe S, Yamada Y, Arai T, Tsushima K, Kondoh Y, Nakamura Y, Terasaki Y, Hebisawa A, Johkoh T, Sakai F, Takemura T, Kawabata Y, Ogura T; Tokyo Diffuse Lung Disease Study Group. Pleuroparenchymal fibroelastosis diagnosed by multidisciplinary discussions in Japan. Respir Med. 2018;141:190-197. [PMID: 30053966 DOI: 10.1016/j.rmed.2018.06.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
113 Kamiya Y, Fujisawa T, Kono M, Nakamura H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Sumikawa H, Johkoh T, Yasui H, Hozumi H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T. Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases. Respir Med 2019;159:105811. [PMID: 31710871 DOI: 10.1016/j.rmed.2019.105811] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
114 Hirabayashi M, Asano Y, Yamashita T, Miura S, Nakamura K, Taniguchi T, Saigusa R, Takahashi T, Ichimura Y, Miyagawa T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S. Possible pro-inflammatory role of heparin-binding epidermal growth factor-like growth factor in the active phase of systemic sclerosis. J Dermatol 2018;45:182-8. [PMID: 29044628 DOI: 10.1111/1346-8138.14088] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
115 Onishi Y, Kawamura T, Higashino T, Kagami R, Hirata N, Miyake K. Clinical features of chronic summer-type hypersensitivity pneumonitis and proposition of diagnostic criteria. Respir Investig 2020;58:59-67. [PMID: 31615746 DOI: 10.1016/j.resinv.2019.09.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
116 d'Alessandro M, Bergantini L, Cavallaro D, Gangi S, Cameli P, Conticini E, Siena Covid Unit, Frediani B, Dotta F, Bargagli E. Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II. Int J Environ Res Public Health 2022;19:2176. [PMID: 35206372 DOI: 10.3390/ijerph19042176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Hambly N, Shimbori C, Kolb M. Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers. Respirology. 2015;20:1010-1022. [PMID: 26109466 DOI: 10.1111/resp.12569] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
118 Sato S, Kato T, Abe K, Hanaoka T, Yano Y, Kurosaki A, Yasuda M, Sekino T, Fujiwara K, Hasegawa K. Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression. Oncol Lett 2017;14:776-86. [PMID: 28693233 DOI: 10.3892/ol.2017.6254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
119 Xu F, Cui W, Wei Y, Dong J, Liu B. Association of serum tumor markers with interstitial lung disease in patients with or without connective tissue disease: A cross-sectional study. Tradit Med Mod Med 2018;01:145-51. [DOI: 10.1142/s2575900018500088] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
120 Bonella F, Long X, Ohshimo S, Horimasu Y, Griese M, Guzman J, Kohno N, Costabel U. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis. Orphanet J Rare Dis 2016;11:48. [PMID: 27108412 DOI: 10.1186/s13023-016-0430-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
121 Yamada H, Okamoto M, Nagasaki Y, Yoshio S, Nouno T, Yano C, Tanaka T, Watanabe F, Shibata N, Arimizu Y, Fukamachi Y, Zaizen Y, Hamada N, Kawaguchi A, Hoshino T, Morita S. Analysis of Early Biomarkers Associated with the Development of Critical Respiratory Failure in Coronavirus Disease 2019 (COVID-19). Diagnostics 2022;12:339. [DOI: 10.3390/diagnostics12020339] [Reference Citation Analysis]
122 Kato K, Lillehoj EP, Lu W, Kim KC. MUC1: The First Respiratory Mucin with an Anti-Inflammatory Function. J Clin Med 2017;6:E110. [PMID: 29186029 DOI: 10.3390/jcm6120110] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
123 Arakawa N, Matsuyama S, Matsuoka M, Kitamura I, Miyashita K, Kitagawa Y, Imai K, Ogawa K, Maeda T, Saito Y, Hasegawa C. Serum stratifin and presepsin as candidate biomarkers for early detection of COVID-19 disease progression. Journal of Pharmacological Sciences 2022;150:21-30. [DOI: 10.1016/j.jphs.2022.06.002] [Reference Citation Analysis]
124 Ji Y, Bourke SJ, Spears M, Wain LV, Boyd G, Lynch PP, Cunningham M, Boyd K, Donnelly I, Kohno N, McSharry C. Krebs von den Lungen-6 (KL-6) is a pathophysiological biomarker of early-stage acute hypersensitivity pneumonitis among pigeon fanciers. Clin Exp Allergy 2020;50:1391-9. [PMID: 32966647 DOI: 10.1111/cea.13744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
125 Ohnishi H, Miyamoto S, Kawase S, Kubota T, Yokoyama A. Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis. BMC Pulm Med 2014;14:129. [PMID: 25098177 DOI: 10.1186/1471-2466-14-129] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
126 Ono T, Iwasaki T, Terada Y, Abe K, Lee J, Mochizuki M, Miyata K. Serum KL-6 elevation in a uveitis patient with Behçet's disease treated with adalimumab. Am J Ophthalmol Case Rep 2020;18:100660. [PMID: 32215341 DOI: 10.1016/j.ajoc.2020.100660] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Konno S, Shigemura M, Ogi T, Shimizu K, Suzuki M, Kaga K, Hida Y, Matsuno Y, Nishimura M. Clinical Course of Histologically Proven Multifocal Micronodular Pneumocyte Hyperplasia in Tuberous Sclerosis Complex: A Case Series and Comparison with Lymphangiomyomatosis. Respiration 2018;95:310-6. [PMID: 29393256 DOI: 10.1159/000486101] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
128 Nakamura M, Okamoto M, Fujimoto K, Ebata T, Tominaga M, Nouno T, Zaizen Y, Kaieda S, Tsuda T, Kawayama T, Hoshino T. A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world. Ann Transl Med 2019;7:262. [PMID: 31355229 DOI: 10.21037/atm.2019.05.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
129 Milara J, Díaz-Platas L, Contreras S, Ribera P, Roger I, Ballester B, Montero P, Cogolludo Á, Morcillo E, Cortijo J. MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease. Respir Res 2018;19:226. [PMID: 30458870 DOI: 10.1186/s12931-018-0927-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
130 Orlova GP, Surkova EA, Lapin SV. Extrinsic interstitial lung disease activity markers. Pulʹmonologiâ (Mosk ) 2016;26:180-5. [DOI: 10.18093/0869-0189-2016-26-2-180-185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
131 Horimasu Y, Hattori N, Ishikawa N, Tanaka S, Bonella F, Ohshimo S, Guzman J, Costabel U, Kohno N. Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPD gene polymorphisms. BMC Med Genet 2014;15:4. [PMID: 24400879 DOI: 10.1186/1471-2350-15-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
132 Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, Masuda S, Okamoto I, Nakagawa T, Ito T, Eto M, Mori M, Nakanishi Y, Egashira N. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. Sci Rep 2021;11:1324. [PMID: 33446685 DOI: 10.1038/s41598-020-79397-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
133 Zhang H, Chen L, Wu L, Huang J, Li H, Wang X, Weng H. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e19493. [PMID: 32311922 DOI: 10.1097/MD.0000000000019493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
134 Horimasu Y, Ishikawa N, Taniwaki M, Yamaguchi K, Hamai K, Iwamoto H, Ohshimo S, Hamada H, Hattori N, Okada M, Arihiro K, Ohtsuki Y, Kohno N. Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. BMC Med Genet 2017;18:88. [PMID: 28821283 DOI: 10.1186/s12881-017-0449-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
135 Zhong D, Wu C, Bai J, Hu C, Xu D, Wang Q, Zeng X. Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis. Medicine (Baltimore) 2020;99:e19695. [PMID: 32311947 DOI: 10.1097/MD.0000000000019695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Ishigooka N, Fujii T, Abe H, Murakami K, Nakashima R, Hashimoto M, Yoshifuji H, Tanaka M, Ito H, Ohmura K, Morita S, Mimori T. Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis. Modern Rheumatology 2020;30:450-7. [DOI: 10.1080/14397595.2019.1621439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
137 Yamakawa H, Hagiwara E, Ikeda S, Iwasawa T, Otoshi R, Tabata E, Okuda R, Sekine A, Baba T, Iso S, Okudela K, Takemura T, Ogura T. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia. Respiratory Investigation 2019;57:422-9. [DOI: 10.1016/j.resinv.2019.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
138 Fouladseresht H, Doroudchi M, Rokhtabnak N, Abdolrahimzadehfard H, Roudgari A, Sabetian G, Paydar S. Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19. Cytokine Growth Factor Rev 2021;58:32-48. [PMID: 33199179 DOI: 10.1016/j.cytogfr.2020.10.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
139 Long X, He X, Ohshimo S, Griese M, Sarria R, Guzman J, Costabel U, Bonella F. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. Eur Respir J 2017;49:1501924. [DOI: 10.1183/13993003.01924-2015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
140 Watanabe S, Kase K, Saeki K, Ohkura N, Murata A, Waseda Y, Takato H, Ichikawa Y, Yasui M, Kasahara K. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease. Respir Med 2021;191:106689. [PMID: 34844174 DOI: 10.1016/j.rmed.2021.106689] [Reference Citation Analysis]
141 Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA; International Workshop on Ocular Sarcoidosis Study Group. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol 2019;103:1418-22. [PMID: 30798264 DOI: 10.1136/bjophthalmol-2018-313356] [Cited by in Crossref: 69] [Cited by in F6Publishing: 49] [Article Influence: 23.0] [Reference Citation Analysis]
142 Chiba H, Otsuka M, Takahashi H. Significance of molecular biomarkers in idiopathic pulmonary fibrosis: A mini review. Respiratory Investigation 2018;56:384-91. [DOI: 10.1016/j.resinv.2018.06.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
143 Ballester B, Milara J, Cortijo J. Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation. Oncotarget 2020;11:1306-20. [PMID: 32341751 DOI: 10.18632/oncotarget.27526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
144 Yoshida N, Okamoto M, Kaieda S, Fujimoto K, Ebata T, Tajiri M, Nakamura M, Tominaga M, Wakasugi D, Kawayama T, Kuwana M, Mimori T, Ida H, Hoshino T. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. Respiratory Investigation 2017;55:24-32. [DOI: 10.1016/j.resinv.2016.08.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
145 Lota HK, Renzoni EA. Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol 2012;2012:121439. [PMID: 22988462 DOI: 10.1155/2012/121439] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
146 Hanata N, Nagafuchi Y, Sugimori Y, Kobayashi S, Tsuchida Y, Iwasaki Y, Shoda H, Fujio K. Serum Amphiregulin and Heparin-Binding Epidermal Growth Factor as Biomarkers in Patients with Idiopathic Inflammatory Myopathy. J Clin Med 2021;10:3730. [PMID: 34442026 DOI: 10.3390/jcm10163730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Masuda T, Yoshida A, Ueno F, Hara S, Nabeta H, Umezawa S, Shirai M, Morikawa Y, Morizane T, Endo Y, Hibi T. A Patient with KL-6 Elevation with Anti-TNFα Who Could Receive Long-Term Use without Interstitial Pneumonia after Class Switch of Anti-TNFα. Inflamm Intest Dis 2019;4:35-40. [PMID: 31172011 DOI: 10.1159/000497778] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Kishaba T, Nei Y, Momose M, Nagano H, Yamashiro S. Clinical Characteristics Based on the New Criteria of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis. Eurasian J Med 2018;50:6-10. [PMID: 29531483 DOI: 10.5152/eurasianjmed.2018.17330] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
149 Bonella F, Long X, He X, Ohshimo S, Griese M, Guzman J, Costabel U. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis: Serum YKL-40 as biomarker for PAP. Respirology 2017;22:1371-8. [DOI: 10.1111/resp.13082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
150 Cao M, Swigris JJ, Wang X, Cao M, Qiu Y, Huang M, Xiao Y, Cai H. Plasma Leptin Is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Mediators Inflamm 2016;2016:6940480. [PMID: 27642238 DOI: 10.1155/2016/6940480] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
151 Salvador-Corres I, Quirant-Sanchez B, Teniente-Serra A, Centeno C, Moreno A, Rodríguez-Pons L, Serra-Mitjá P, García-Nuñez M, Martinez-Caceres E, Rosell A, Olivé A, Portillo K. Detection of Autoantibodies in Bronchoalveolar Lavage in Patients with Diffuse Interstitial Lung Disease. Arch Bronconeumol (Engl Ed) 2021;57:351-8. [PMID: 33069461 DOI: 10.1016/j.arbres.2020.08.020] [Reference Citation Analysis]
152 Glick D, Lyen S, Kandel S, Shapera S, Le LW, Lindsay P, Wong O, Bezjak A, Brade A, Cho BCJ, Hope A, Sun A, Giuliani M. Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT). Clin Lung Cancer 2018;19:e219-26. [PMID: 29066051 DOI: 10.1016/j.cllc.2017.06.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
153 Xie XH, Deng HY, Lin XQ, Wu JH, Liu M, Xie ZH, Qin YY, Zhou CZ. Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer. Front Oncol 2021;11:673877. [PMID: 34221992 DOI: 10.3389/fonc.2021.673877] [Reference Citation Analysis]
154 Wang Y, Chen S, Lin Z, Lin J, Xie X, Lin Q, Du G, Huang X, Matucci-Cerinic M, Furst DE. Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review. Clin Rheumatol 2019;38:1433-6. [PMID: 30746580 DOI: 10.1007/s10067-019-04462-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
155 Amat F, Henquell C, Verdan M, Roszyk L, Mulliez A, Labbé A. Predicting the severity of acute bronchiolitis in infants: should we use a clinical score or a biomarker? J Med Virol 2014;86:1944-52. [PMID: 24374757 DOI: 10.1002/jmv.23850] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
156 Elhai M, Avouac J, Allanore Y. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand? Semin Arthritis Rheum 2020;50:480-91. [PMID: 32089354 DOI: 10.1016/j.semarthrit.2020.01.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
157 Kato K, Zemskova MA, Hanss AD, Kim MM, Summer R, Kim KC. Muc1 deficiency exacerbates pulmonary fibrosis in a mouse model of silicosis. Biochemical and Biophysical Research Communications 2017;493:1230-5. [DOI: 10.1016/j.bbrc.2017.09.047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
158 Peng DH, Luo Y, Huang LJ, Liao FL, Liu YY, Tang P, Hu HN, Chen W. Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019. Clin Chim Acta 2021;517:48-53. [PMID: 33631198 DOI: 10.1016/j.cca.2021.02.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
159 Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2014;307:L681-91. [PMID: 25260757 DOI: 10.1152/ajplung.00014.2014] [Cited by in Crossref: 113] [Cited by in F6Publishing: 94] [Article Influence: 14.1] [Reference Citation Analysis]
160 Zheng M, Lou A, Zhang H, Zhu S, Yang M, Lai W. Serum KL-6, CA19-9, CA125 and CEA are Diagnostic Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Chinese Population. Rheumatol Ther 2021;8:517-27. [PMID: 33586127 DOI: 10.1007/s40744-021-00288-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
161 Milara J, Ballester B, Montero P, Escriva J, Artigues E, Alós M, Pastor-Clerigues A, Morcillo E, Cortijo J. MUC1 intracellular bioactivation mediates lung fibrosis. Thorax 2020;75:132-42. [PMID: 31801904 DOI: 10.1136/thoraxjnl-2018-212735] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
162 Ishii H, Kinoshita Y, Kushima H, Nagata N, Watanabe K. The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis. Chron Respir Dis 2019;16:1479973119867945. [PMID: 31387379 DOI: 10.1177/1479973119867945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
163 Wakui H, Tanaka Y, Ose T, Matsumoto I, Kato K, Min Y, Tachibana T, Sato M, Naruchi K, Martin FG, Hinou H, Nishimura SI. A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes. Chem Sci 2020;11:4999-5006. [PMID: 34122956 DOI: 10.1039/d0sc00317d] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
164 Fu Y, Yu Q, Zhang Q, Zhang X, Du C, Chen J. A photocurrent-polarity-switching biosensor for highly selective assay of mucin 1 based on target-induced hemin transfer from ZrO2 hollow spheres to G-quadruplex nanowires. Biosens Bioelectron 2021;192:113547. [PMID: 34385013 DOI: 10.1016/j.bios.2021.113547] [Reference Citation Analysis]
165 Shtraichman O, Diamond JM. Emerging biomarkers in chronic lung allograft dysfunction. Expert Rev Mol Diagn 2020;20:467-75. [PMID: 32133875 DOI: 10.1080/14737159.2020.1738929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
166 Chen F, Lu X, Shu X, Peng Q, Tian X, Wang G. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study: Predictive value of serum markers. Intern Med J 2015;45:641-7. [DOI: 10.1111/imj.12754] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
167 Bergantini L, Bianchi F, Cameli P, Mazzei MA, Fui A, Sestini P, Rottoli P, Bargagli E. Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6. Dis Markers 2019;2019:8565423. [PMID: 30944672 DOI: 10.1155/2019/8565423] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
168 Costabel U, Miyazaki Y, Pardo A, Koschel D, Bonella F, Spagnolo P, Guzman J, Ryerson CJ, Selman M. Hypersensitivity pneumonitis. Nat Rev Dis Primers 2020;6:65. [PMID: 32764620 DOI: 10.1038/s41572-020-0191-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
169 Giacomelli C, Piccarducci R, Marchetti L, Romei C, Martini C. Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients. Biochem Pharmacol 2021;193:114812. [PMID: 34687672 DOI: 10.1016/j.bcp.2021.114812] [Reference Citation Analysis]
170 Togashi Y, Kono Y, Okuma T, Shioiri N, Mizushima R, Tanaka A, Ishiwari M, Toriyama K, Kikuchi R, Takoi H, Abe S. Surfactant protein D: A useful biomarker for distinguishing COVID‐19 pneumonia from COVID‐19 pneumonia‐like diseases. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.622] [Reference Citation Analysis]
171 Kost-Alimova M, Sidhom EH, Satyam A, Chamberlain BT, Dvela-Levitt M, Melanson M, Alper SL, Santos J, Gutierrez J, Subramanian A, Byrne PJ, Grinkevich E, Reyes-Bricio E, Kim C, Clark AR, Watts AJB, Thompson R, Marshall J, Pablo JL, Coraor J, Roignot J, Vernon KA, Keller K, Campbell A, Emani M, Racette M, Bazua-Valenti S, Padovano V, Weins A, McAdoo SP, Tam FWK, Ronco L, Wagner F, Tsokos GC, Shaw JL, Greka A. A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. Cell Rep Med 2020;1:100137. [PMID: 33294858 DOI: 10.1016/j.xcrm.2020.100137] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
172 Zhang K, Wang J, Jiang H, Xu X, Wang S, Zhang C, Li Z, Gong X, Lu W. Tanshinone IIA inhibits lipopolysaccharide-induced MUC1 overexpression in alveolar epithelial cells. Am J Physiol Cell Physiol 2014;306:C59-65. [PMID: 24153432 DOI: 10.1152/ajpcell.00070.2013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
173 Celeste S, Santaniello A, Caronni M, Franchi J, Severino A, Scorza R, Beretta L. Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients. European Journal of Internal Medicine 2013;24:671-6. [DOI: 10.1016/j.ejim.2013.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
174 Chen H, Qin R, Huang Z, Luo W, Zheng P, Huang H, Hu H, Wang H, Sun B. Clinical relevance of serum Krebs von den Lungen-6 levels in patients with coronavirus disease 2019. Cytokine 2021;148:155513. [PMID: 34507246 DOI: 10.1016/j.cyto.2021.155513] [Reference Citation Analysis]
175 Tomita M, Ayabe T, Chosa E, Nose N, Nakamura K. Prognostic Significance of a Tumor Marker Index Based on Preoperative Serum Carcinoembryonic Antigen and Krebs von den Lungen-6 Levels in Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev 2017;18:287-91. [PMID: 28240848 DOI: 10.22034/APJCP.2017.18.1.287] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
176 Chung C, Kim J, Cho HS, Kim HC. Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis. Sci Rep 2022;12:8564. [PMID: 35595812 DOI: 10.1038/s41598-022-12399-8] [Reference Citation Analysis]
177 Onishi Y, Kawamura T, Higashino T, Mimura R, Tsukamoto H, Sasaki S. Clinical features of acute fibrinous and organizing pneumonia: An early histologic pattern of various acute inflammatory lung diseases. PLoS One 2021;16:e0249300. [PMID: 33793625 DOI: 10.1371/journal.pone.0249300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
178 Ko UW, Cho EJ, Oh HB, Koo HJ, Do KH, Song JW. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease. PLoS One 2020;15:e0244114. [PMID: 33332430 DOI: 10.1371/journal.pone.0244114] [Reference Citation Analysis]
179 Puxeddu E, Rogliani P. Prognostic scoring systems for clinical course and survival in idiopathic pulmonary fibrosis. World J Respirol 2016; 6(1): 14-23 [DOI: 10.5320/wjr.v6.i1.14] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
180 Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr Opin Pulm Med 2015;21:470-8. [PMID: 26132817 DOI: 10.1097/MCP.0000000000000187] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
181 White ES, Thomas M, Stowasser S, Tetzlaff K. Challenges for Clinical Drug Development in Pulmonary Fibrosis. Front Pharmacol 2022;13:823085. [DOI: 10.3389/fphar.2022.823085] [Reference Citation Analysis]
182 Yamagishi T, Kodaka N, Watanabe K, Nakano C, Oshio T, Niitsuma K, Shimada N, Matsuse H. A retrospective clinical research of relapsed organizing pneumonia. Ann Thorac Med 2020;15:15-20. [PMID: 32002042 DOI: 10.4103/atm.ATM_311_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
183 Cao XY, Hu SS, Xu D, Li MT, Wang Q, Hou Y, Zeng XF. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort. Int J Rheum Dis 2019;22:108-15. [PMID: 30592376 DOI: 10.1111/1756-185X.13452] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
184 Matsumura T, Tsushima K, Abe M, Suzuki K, Yamagishi K, Matsumura A, Ichimura Y, Ikari J, Terada J, Tatsumi K. The effects of pirfenidone in patients with an acute exacerbation of interstitial pneumonia. Clin Respir J 2018;12:1550-8. [DOI: 10.1111/crj.12704] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
185 Sawazumi T, Baba T, Iwasawa T, Arai H, Matsumura M, Takemura T, Sugiyama M, Sekiya M, Saigusa Y, Ogura T, Inayama Y, Ohashi K, Okudela K. Prognostic impact of HNF4α expression in interstitial lung disease. Pathol Int 2021. [PMID: 34643024 DOI: 10.1111/pin.13176] [Reference Citation Analysis]
186 Watanabe K. Pleuroparenchymal Fibroelastosis: Its Clinical Characteristics. Curr Respir Med Rev 2013;9:299-37. [PMID: 24578677 DOI: 10.2174/1573398X0904140129125307] [Cited by in Crossref: 56] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
187 Lillehoj EP, Luzina IG, Atamas SP. Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond. Front Immunol 2022;13:883079. [DOI: 10.3389/fimmu.2022.883079] [Reference Citation Analysis]
188 Saitoh Y, Aoshima Y, Mukai T, Abe H, Ariga H, Mori-Yoshimura M, Okamoto T, Takahashi Y. Riluzole-induced interstitial lung disease is a rare and potentially life-threatening adverse event successfully treated with high-dose steroid therapy: Case reports and review of the literature. J Neurol Sci 2020;410:116650. [PMID: 31901592 DOI: 10.1016/j.jns.2019.116650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
189 Horimasu Y, Hattori N, Ishikawa N, Kawase S, Tanaka S, Yoshioka K, Yokoyama A, Kohno N, Bonella F, Guzman J, Ohshimo S, Costabel U. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respiratory Medicine 2012;106:1756-64. [DOI: 10.1016/j.rmed.2012.09.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
190 Agache IO, Rogozea L. Management of hypersensivity pneumonitis. Clin Transl Allergy 2013;3:5. [PMID: 23374544 DOI: 10.1186/2045-7022-3-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
191 Hanzawa S, Tateishi T, Ishizuka M, Inoue Y, Honda T, Kawahara T, Tomita M, Miyazaki Y. Changes in serum KL-6 levels during short-term strict antigen avoidance are associated with the prognosis of patients with fibrotic hypersensitivity pneumonitis caused by avian antigens. Respir Investig 2020;58:457-64. [PMID: 32698996 DOI: 10.1016/j.resinv.2020.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
192 Naderi N, Rahimzadeh M. Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses. Virology 2022;566:106-13. [PMID: 34896901 DOI: 10.1016/j.virol.2021.11.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, Kirino Y, Sugiyama Y, Tanino Y, Nunokawa T, Kaneko Y, Sato S, Asakawa K, Ukichi T, Kaieda S, Naniwa T, Okano Y, Kuwana M; the Multicenter Retrospective Cohort of Japanese Patients with Myositis-Associated ILD (JAMI) Investigators. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease. Arthritis Rheumatol 2021;73:677-86. [PMID: 33118321 DOI: 10.1002/art.41566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
194 Utsunomiya A, Oyama N, Hasegawa M. Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. J Clin Med 2020;9:E3388. [PMID: 33105647 DOI: 10.3390/jcm9113388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
195 Tajiri M, Okamoto M, Fujimoto K, Johkoh T, Ono J, Tominaga M, Azuma K, Kawayama T, Ohta S, Izuhara K, Hoshino T. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Respir Investig 2015;53:73-81. [PMID: 25745852 DOI: 10.1016/j.resinv.2014.12.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]